Cingulate Announces Strategic Partnership with Bend Bio Sciences
Cingulate Inc. (NASDAQ: CING), a pioneering biopharmaceutical company based in Kansas City, has formed an exclusive collaboration with Bend Bio Sciences. This agreement is designed to focus on the manufacturing of CTx-1301, an innovative medication aimed at treating attention deficit/hyperactivity disorder (ADHD). Cingulate's unique Precision Timed Release™ (PTR™) technology, which ensures optimal release of medication, plays a vital role in this partnership.
Advantages of CTx-1301 in ADHD Treatment
CTx-1301 is a state-of-the-art extended-release tablet formulation of dexmethylphenidate HCl, setting out to overcome significant challenges faced by existing ADHD therapies. This medication aims to provide a longer duration of symptom relief than traditional options, potentially helping millions who struggle with attention-related issues. With the NDA submitted to the FDA for CTx-1301, Cingulate is preparing for a significant impact in the ADHD treatment landscape.
Commitment to Manufacturing Precision and Quality
As part of the agreement with Bend Bio Sciences, they will be the exclusive manufacturer of CTx-1301 in the United States, contingent on FDA approval. Cingulate has committed to source 100% of its U.S. supply from Bend, underscoring their dedication to ensuring manufacturing efficiency and reliability. Jay Roberts, Executive Chairman of Cingulate, emphasized, “This strategic partnership not only secures our manufacturing capabilities but also reinforces our pledge to deliver a consistent, high-quality supply of CTx-1301 to those who need it.”
Expert Insights from Bend Bio Sciences
Owen Murray, CEO of Bend Bio Sciences, expressed excitement about the collaboration, citing the complex nature of the multi-phase release tablet as a perfect match for their technical expertise. This partnership reflects a shared commitment to developing therapies centered on patient needs and enhancing treatment outcomes.
Understanding ADHD and its Impact
Attention deficit/hyperactivity disorder (ADHD) affects a substantial number of individuals, predominantly children, yet often persists into adulthood. The CDC reported that only 53.6% of children and teens with ADHD were reported to be receiving medication in 2022, while a large number display symptoms that continue through their adult years. ADHD prevalence in adults is on the rise, indicating an urgent need for effective treatment options.
Innovative Drug Delivery with the PTR Platform
Cingulate’s PTR platform technology is engineered to deliver medications with high precision, enabling true once-daily dosing for patients. This platform introduces a proprietary Erosion Barrier Layer (EBL) that regulates drug release at defined intervals, ensuring optimal therapeutic levels are maintained throughout the day. As Cingulate advances this technology, it is also exploring other therapeutic areas beyond ADHD.
Future Growth and Development of Cingulate
As a biopharmaceutical company focused on improving the lives of patients, Cingulate remains dedicated to researching and developing new therapeutic candidates utilizing the PTR technology. Their mission is to enhance treatment outcomes for conditions that require complex dosing regimens, establishing themselves as leaders in innovative drug delivery solutions.
About Cingulate Inc. and Bend Bio Sciences
Cingulate Inc. is committed to transforming pharmaceuticals using their proprietary technology. Bend Bio Sciences, formed from the merger of three leading CDMOs, is dedicated to providing robust scientific solutions and quality in the manufacturing of complex drug formulations. Both companies share a vision of advancing healthcare through collaboration and innovation.
Frequently Asked Questions
What is CTx-1301?
CTx-1301 is a novel extended-release formulation of dexmethylphenidate HCl developed for the treatment of ADHD.
How will the partnership with Bend Bio Sciences benefit Cingulate?
This collaboration ensures that Cingulate has a reliable manufacturing partner for CTx-1301, enhancing efficiency and quality in production.
What sets the PTR technology apart?
Cingulate's PTR technology allows for precise control of drug release, enabling effective once-daily dosing and addressing patient needs.
Why is ADHD an important focus for Cingulate?
ADHD is a prevalent condition affecting millions, and effective treatments are crucial for improving patients' quality of life.
What are the potential future developments for Cingulate?
Cingulate plans to explore additional therapeutic areas where its PTR technology can be applied to enhance treatment outcomes.
